Full disclaimer 1.AOD-9604 is a 16-amino acid peptide fragment derived from human growth hormone (hGH residues 177-191) with added tyrosine, developed by Metabolic Pharmaceuticals for obesity treatment 2.Proposed mechanism: selective stimulation of lipolysis (fat breakdown) and inhibition of lipogenesis (fat formation) without growth hormone-like effects on IGF-1 or blood glucose 3.Failed Phase 2b clinical trial for obesity (2007)did not demonstrate statistically significant weight loss versus placebo, terminating clinical development for this indication 4.Received FDA "Generally Recognized as Safe" (GRAS) designation in 2023 as a food substance, but this is NOT a drug approval and does not establish efficacy for weight loss 5.Regulatory status: not FDA-approved as a drug, prohibited by WADA, and insufficient evidence for weight loss efficacy
AOD-9604 contains the hGH 177191 sequence with an added tyrosine at the N-terminus (for stabilisation), whereas HGH Fragment 176-191 is one amino acid shorter and unstabilised
Heres what Midis team of medical experts currently recommend: If you generally want to improve gut health: Make sure you have foundational gut-health habits in check, like getting plenty of fiber and staying hydrated
Its small molecular weight (~390 Da) supports cellular uptake and is reported to enable direct DNA / chromatin interaction at gene promoter regions, consistent with the broader Khavinson bioregulator hypothesis
CJC-1295, Ipamorelin, Tesamorelin, and Sermorelin are typically administered subcutaneously, usually in the abdomen
